[1]
|
xJ. B. Gibbs, “Mechanism-based target identification and drug discovery in cancer research,” Science, Vol. 287, pp. 1969–1973, 2000.
|
[2]
|
B. A. Chabner, W. Wilson, and J. Supko, “Pharmacology and toxicity of antineoplastic drugs,” In: E. Beutler, M. A. Lichtman, B. S. Coller, T. J. Kipps, U. Seligsoh, Ed., Williams Hematology, 6th edition, McGraw Hill, New York, pp. 185, 2001.
|
[3]
|
X. Fuchun, Z. Hongbing, Z. Lizhi, L. Liguang, and H. Youhong, “Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity,” Bioorganic and Medicinal Chemistry Letters, Vol. 19, pp. 275–278, 2009.
|
[4]
|
D. G. Monica, A. G. V. Jose, R. S. Fernando, A. M. Juan, C. Octavio, A. Antonia, A. G. Miguel, E. Antonio, and M. C. Joaquin, “Anticancer activity of (1,2,3,5-tetrahydro-4, 1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies,” Bioorganic and Medicinal Chemistry Letters, Vol. 18, pp. 1457–1460, 2008.
|
[5]
|
S. Nilantha, K. Shailaja, N. Bao, P. Azra, W. Yang, C. Gisela, T. Ben, D. John, and X. C. Sui, “Discovery of substituted 4-anilino-2-(2-pyridyl) pyrimidines as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay,” Part 1: Structure-activity relationships of the 4-anilino group, Bioorganic and Medicinal Chemistry Letters, Vol. 14, pp. 7761–7773, 2006.
|
[6]
|
S. S. Bahekar and D. B. Shinde, “Synthesis and anti-inflammatory activity of some [4,6-(4-substituted aryl)-2-thioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl]-acetic acid deri vatives,” Bioorganic and Medicinal Chemistry Letters, Vol. 14, pp. 1733–1736, 2004.
|
[7]
|
K. Tadashi, I. Motonobu, H. Akio, K. Fumihiko, and K. Kazuo, “Pyrimidine nucleosides. 6. Synthesis and anti-cancer activities of N4-substituted 2,2'-anhydronucleosides,” Journal of Medicinal Chemistry, Vol. 17, pp. 1076–1078, 1974.
|
[8]
|
S. L. Tai, H. Y. Jing, C. L. Mao, Y. S. Zh, C. C. Yung, H. P. William, I. B. George, G. Jerzy, and G. Ismail, “Synthesis and anticancer activity of various 3'-deoxy pyrimidine nucleoside analogs, and crystal structure of 1-(3-deoxy-. beta.-D-threo-pentofuranosyl) cytosine,” Journal of Medicinal Chemistry, Vol. 34, pp. 693–701, 1991.
|
[9]
|
N. Ebrahim, Z. Aihua, K. Panteh, I. W. Leonard, B. Jan, D. C. Erik, and E. K. Edward, “Synthesis of 3‘- and 5‘-nitrooxy pyrimidine nucleoside nitrate esters: ‘Nitric Oxide Donor’ agents for evaluation as anticancer and antiviral agents,” Journal of Medicinal Chemistry, Vol. 46, pp. 995–1004, 2003.
|
[10]
|
G. N. Pershin, L. I. Sherbakova, T. N. Zykova, and V. N. Sakolova, “Antibacterial activity of pyrimidineand pyrrolo-(3, 2-d)-pyrimidine derivatives,” Farmakol Taksikol, Vol. 35, pp. 466–471, 1972.
|
[11]
|
D. J. Brown, “Pyrimidines and their benzo derivatives,” In: A. R. Katrizky, C. W. Rees Ed., Comprehensive heterocyclic chemistry, the structure, reactions, synthesis and uses of heterocyclic compounds, Pragmon Press, Oxford, pp. 57, 1984.
|
[12]
|
N. I. Smetskaya, N. A. Mukhina, V. G. Granik, G. Y. Shvarts, R. D. Syubaev, and M. D.Mashkovskii, “Synthesis and study of analgesic action of pyrido [1,2-a] pyrimidine derivatives,” Pharmaceutical Chemistry Journal, Vol. 18, pp. 540–544, 1984.
|
[13]
|
S. Naresh, Nishi, P. Shraddha, M. S. C. Prem, and G. Suman, “Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines,” European Journal of Medicinal Chemistry, Vol. 44, pp. 2473–2481, 2009.
|
[14]
|
A. Z. Medhat, M. S. Ahmed, S. A. E. Mohamed, A. A. Yousry, and H. E. Usama, “Some reactions with Ketene dithioacetals: Part I: Synthesis of antimicrobial pyrazolo [1,5-a] pyrimidines via the reaction of ketene dithioacetals and 5-aminopyrazoles,” Il Farmaco, Vol. 56, pp. 277–283, 2001.
|
[15]
|
E. T. Buurman, A. E. Blodgett, K. G. Hull, and D. Carcanague, “Pyridines and pyrimidines mediating activity against an efflux-negative strain of candida albicans through putative inhibition of lanosterol demethylase,” Antimicrob Agents Chemother, Vol. 48, pp. 313–318, 2004.
|
[16]
|
P. J. Manley, A. E. Balitza, M. T. Bilodeau, K. E. Coll, G. D. Hartman, R. C. McFall, K. W. Rickert, L. D. Rodman, and K. A. Thomas, “2, 4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, Vol. 13, pp. 1673–1677, 2003.
|
[17]
|
M. Anderson, J. F. Beattie, G. A. Breault, J. Breed, K. F. Byth, J. D. Culshaw, R. P. A. Ellston, S. Green, C. A. Minshull, R. A. Norman, R. A. Pauptit, J. Stanway, A. P. Thomas, and P. J. Jewsbury, “Imidazo [1,2-a] pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridization,” Bioorganic and Medicinal Chemistry Letters, Vol. 13, pp. 3021–3026, 2003.
|
[18]
|
K. F. Byth, J. D. Culshaw, S. Green, S. E. Oakes, and A. P. Thomas, “Imidazo [1,2-a] pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, Vol. 14, pp. 2245–2248, 2004.
|
[19]
|
S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D’Andrea, M. Reuman, G. Bignan, R. Tuman, D. Johnson, D. Moffatt, M. Batchelor, A. Foley, J. O’Connell, R. Allen, M. Perry, L. Jolliffe, and S. A. Middleton, “A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models,” Molecular Pharmacology, Vol. 66, pp. 635, 2004.
|
[20]
|
J. T. Sisko, T. J. Tucker, M. T. Bilodeau, C. A. Buser, P. A. Ciecko, K. E. Coll, C. Fernandes, J. B. Gibbs, T. J. Koester, N. Kohl, J. J. Lynch, X. Mao, D. McLoughlin, C. M. Miller-Stein, L. D. Rodman, K. W. Rickert, L. Sepp-Lorenzino, J. M. Shipman, K. A. Thomas, B. K. Wong, and G. D. Hartman, “Potent 2-[(pyrimidin-4-yl) amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase,” Bioorganic and Medicinal Chemistry Letters, Vol. 16, pp. 1146–1150, 2004.
|
[21]
|
A. G. Waterson, K. L. Stevens, M. J. Reno, Y. M. Zhang, E. E. Boros, F. Bouvier, A. Rastagar, D. E. Uehling, S. H. Dickerson, B. Reep, O. B. McDonald, E. R. Wood, D. W. Rusnak, K. J. Alligood, and S. K. Rudolph, “Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, Vol. 16, pp. 2419–2422, 2006.
|
[22]
|
G. A. Breault, R. P. A. Ellston, S. Green, S. R. James, P. J. Jewsbury, C. J. Midgley, R. A. Pauptit, C. A. Minshull, J. A. Tucker, and J. E. Pease, “Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: Identification and optimisation of substituted 2, 4-bis anilino pyrimidines,” Bioorganic and Medicinal Chemistry Letters, Vol. 13, pp. 2961–2966, 2003.
|
[23]
|
J. F. Beattie, G. A. Breault, R. P. A. Ellston, S. Green, P. J. Jewsbury, C. J. Midgley, R. T. Naven, C. A. Minshull, R. A. Pauptit, J. A. Tucker, and J. E. Pease, “Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: Identification and optimisation of substituted 4, 6-Bis anilino pyrimidines,” Bioorganic and Medicinal Chemistry Letters, Vol. 13, pp. 2955–2960, 2003.
|
[24]
|
Q. Zhang, Y. Liu, F. Gao, Q. Ding, C. Cho, W. Hur, Y. Jin, T. Uno, C. A. P. Joazeiro, and N. Gray, “Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library,” Journal of the American Chemical Society, Vol. 128, pp. 2182–2183, 2006.
|
[25]
|
V. J. Cee, B. K. Albrecht, S. Geuns-Meyer, P. Hughes, S. Bellon, J. Bready, S. Caenepeel, S. C. Chaffee, A. Coxon, M. Emery, J. Fretland, P. Gallant, Y. Gu, B. L. Hodous, D. Hoffman, R. E. Johnson, R. Kendall, J. L. Kim, A. M. Long, D. McGowan, M. Morrison P. R. Olivieri, V. F. Patel, A. Polverino, D. Powers, P. Rose, L. Wang, and H. Zhao, “Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of tie-2 kinase,” Journal of Medicinal Chemistry, Vol. 50, pp. 627–640, 2007.
|
[26]
|
G. W. Rewcastle, W. A. Denny, and H. D. H. Showalter, “Synthesis of 4-(Phenylamino) pyrimidine derivatives as atp-competitive protein kinase inhibitors with potential for cancer chemotherapy,” Current Organic Chemistry, Vol. 4, pp. 679–706, 2000.
|
[27]
|
A. J. Bridges, “Chemical inhibitors of protein kinases,” Chemical Reviews, Vol. 101, pp. 2541–2572, 2001.
|
[28]
|
P. Traxler, E. Bold, G. Buchdunger, G. Caravatti, P. Furet, P. Manley, T. O’Reilly, J. Wood, and J. Zimmermann, “Tyrosine kinase inhibitors: From rational design to clinical trials,” Medicinal Research Reviews, Vol. 21, pp. 499–512, 2001.
|
[29]
|
D. S. Prasanna, C. V. Kavitha, B. Raghava, K. Vinaya, S. R. Ranganatha, S. C. Raghavan, and K. S. Rangappa, “Synthesis and identification of a new class of (S)-2,6-diamino-4,5,6,7-tetrahydrobenzo[d]thiazole derivatives as potent antileukemic agents,” Investigational New Drugs, 2009.
|
[30]
|
C. S. Ananda-Kumar, C. V. Kavitha, K. Vinaya, S. B. Benaka Prasad, N. R. Thimmegowda, S. Chandrappa, S. C. Raghavan, and K. S. Rangappa, “Synthesis and in vitro cytotoxic evaluation of novel diazaspiro bicyclo hydantoin derivatives in human leukemia cells: A SAR study,” Investigational New Drugs, Vol. 27, pp. 327–337, 2009.
|
[31]
|
C. V. Kavitha, M. Nambiar, C. S. Ananda-Kumar, B. Choudhary, K. Muniyappa, K. S. Rangappa, and S. C. Raghavan, “Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells,” Biochemical Pharmacology, Vol. 77, pp. 348–363, 2009.
|
[32]
|
S. Chandrappa, C. V. Kavitha, M. S. Shahabuddin, K. Vinaya, C. S. Ananda-Kumar, S. R. Ranganatha, S. C. Raghavan, and K. S. Rangappa, “Synthesis of 2-(5-((5-(4-chlorophenyl)furan-2-yl) methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid derivatives and evaluation of their cytotoxicity and induction of apoptosis in human leukemia cells,” Bioorganic and Medicinal Chemistry, Vol. 17, pp. 2576–2584, 2009.
|
[33]
|
D. Asha, Manish Malviya., S. Chandrappa, , C. T. Sadashiva, K. Vinaya, D. S. Prasanna and K. S. Rangappa, “Synthesis and characterization of substituted ethyl 2-(1-aminocyclobutyl)-5-(benzoyloxy)-6-hydroxypyrimi-dine-4-carboxylate derivatives as antioxidant agents,” Letters in Drug Design and Discovery, Vol. 6, No. 8, pp. 637–643, 2009.
|